This is a trivial insider sale proposal by a venture affiliate; the dollar amount is immaterial. No immediate action warranted. Monitor for any large-scale insider selling patterns, but this single filing is not a signal of deterioration.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 26 $20.94entry
- T+1 · 5mo ago +1.53%α −0.12% · $21.26
- T+5 · 4mo ago +10.17%α +8.01% · $23.07
- T+20 · 4mo ago +14.09%α +12.83% · $23.89
- T+60 · 8w ago −18.24%α −24.35% · $17.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Atlas Venture Opportunity Fund I, L.P., a venture capital affiliate, filed a Form 144 indicating intent to sell 5,019 shares of Dyne Therapeutics (DYN) common stock, with an estimated value of approximately $102,036. The shares were acquired via private placement in August 2020. The proposed sale is negligible relative to DYN's $3.6B market cap and appears routine portfolio management by a significant early investor.
Key Facts
- Reporting owner: Atlas Venture Opportunity Fund I, L.P.
- Proposed sale: 5,019 shares of DYN common stock
- Estimated market value: $102,036.27 as of June 25, 2026
- Shares acquired via private placement on August 7, 2020
- Broker: Merrill Lynch
- Filing date: June 25, 2026
Financial Impact
Proposed sale of 5,019 shares ($102,036.27), negligible relative to DYN's $3.6B market cap
Risk Factors
- Sale may be executed, but volume is too small to affect stock price or liquidity
- No risk of material dilution or insider sentiment shift from this filing alone
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-045612 |
| Document: 0001628280-26-045612-index.html | 0001628280-26-045612 |
| Document: 0001628280-26-045612.txt | 0001628280-26-045612 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers